AChE-IN-9 

AChE-IN-9 is a Tacrine (HY-111338) glycoconjugate tethered with acetylated β-Glucose. AChE-IN-9 is also an AChE inhibitor with an IC₅₀ value of 0.4 μM, with lower hepatotoxicity on healthy cells. Tacrine is used in Alzheimer's research^[1].

0.4 μM (AChE)^[1]

Tacrine (HY-111338) is mainly metabolized by CYP 1A2, but its glycoconjugates have shown more affinity towards CYP 3A4 rather than CYP 1A2^[1].
AChE-IN-9 (compound A-1) (200 μM; 24 h) is non-toxic on HePG2 cell line with 100% cell viability, and shows lower hepatotoxicity than Tacrine (HY-111338) on healthy HepG2 cells^[1].
AChE-IN-9 (10 μM; 24 h) inhibits AChE activity with inhibition rate of 96.6%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

609.63

C₃₀H₃₅N₅O₉

CC(OC[C@H]1O[C@@H]([C@@H]([C@H]([C@@H]1OC(C)=O)OC(C)=O)OC(C)=O)N2C=C(N=N2)CNC3=C4CCCCC4=NC5=CC=CC=C53)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kaur Gulati H, et al. Design, Synthesis, biological investigations and molecular interactions of triazole linked tacrine glycoconjugates as Acetylcholinesterase inhibitors with reduced hepatotoxicity. Bioorg Chem. 2022 Jan;118:105479.  [Content Brief]